Hepatitis B virus and HIV infection

Area of Science:

• Hepatology
• Virology
• Infectious Diseases

Background:

• 5-10% of human immunodeficiency virus (HIV)-infected individuals globally are coinfected with chronic hepatitis B virus (HBV).
• HIV/HBV coinfection accelerates liver disease progression, leading to higher rates of cirrhosis and liver-related mortality compared to HBV monoinfection.
• Therapeutic management of coinfection is a priority due to increased disease severity.

Purpose of the Study:

• To review the natural history of HIV/HBV coinfection.
• To provide updated guidance on optimal drug selection for treating coinfected patients.
• To discuss concerns regarding drug resistance and vaccine escape mutants.

Main Methods:

• Literature review of current research on HIV/HBV coinfection.
• Analysis of antiviral drug activity against both HIV and HBV.
• Examination of resistance patterns and implications for treatment.

Main Results:

• Certain antiretrovirals (tenofovir, lamivudine, emtricitabine) are effective against both HIV and HBV and recommended for coinfected patients.
• HBV-specific antivirals (entecavir, adefovir) may have residual HIV activity but can select for HIV resistance mutations.
• Careful drug selection within potent antiretroviral therapy is essential.

Conclusions:

• Optimal management of HIV/HBV coinfection necessitates dual-acting antiviral agents.
• Vigilance regarding potential drug resistance and vaccine escape is critical.
• Personalized treatment strategies are key to improving outcomes in coinfected individuals.